{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:38:46Z","timestamp":1792784326095,"version":"4.5.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Daiichi Sankyo Co. Ltd"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.semarthrit.2019.02.003","type":"journal-article","created":{"date-parts":[[2019,2,10]],"date-time":"2019-02-10T14:06:56Z","timestamp":1549807616000},"page":"204-210","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Anti-nuclear antibody development is associated with poor treatment response to biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis"],"prefix":"10.1016","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6514-8239","authenticated-orcid":false,"given":"Yuki","family":"Ishikawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motomu","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromu","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masao","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoichiro","family":"Yukawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takao","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuneyo","family":"Mimori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chikashi","family":"Terao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.semarthrit.2019.02.003_bib0001","doi-asserted-by":"crossref","first-page":"R213","DOI":"10.1186\/ar3546","article-title":"Correlation of antinuclear antibody and anti-double-stranded DNA antibody with clinical response to infliximab in patients with rheumatoid arthritis: a retrospective clinical study","volume":"13","author":"Yukawa","year":"2011","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"10.1016\/j.semarthrit.2019.02.003_bib0002","first-page":"175","article-title":"One year in review 2018: pathogenesis of rheumatoid arthritis","volume":"36","author":"Calabresi","year":"2018","journal-title":"Clin Exp Rheumatol"},{"issue":"6","key":"10.1016\/j.semarthrit.2019.02.003_bib0003","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1136\/annrheumdis-2016-210713","article-title":"Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis","volume":"76","author":"Nam","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"14","key":"10.1016\/j.semarthrit.2019.02.003_bib0004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta15140","article-title":"Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation","volume":"15","author":"Malottki","year":"2011","journal-title":"Health Technol Assess"},{"issue":"1","key":"10.1016\/j.semarthrit.2019.02.003_bib0005","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/BOR.0b013e32835b1366","article-title":"Biologics-induced autoimmune diseases","volume":"25","author":"Perez-Alvarez","year":"2013","journal-title":"Curr Opin Rheumatol"},{"issue":"3","key":"10.1016\/j.semarthrit.2019.02.003_bib0006","doi-asserted-by":"crossref","first-page":"e59341","DOI":"10.1371\/journal.pone.0059341","article-title":"Three groups in the 28 joints for rheumatoid arthritis synovitis\u2013analysis using more than 17,000 assessments in the KURAMA database","volume":"8","author":"Terao","year":"2013","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.semarthrit.2019.02.003_bib0007","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","article-title":"The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis","volume":"31","author":"Arnett","year":"1988","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.semarthrit.2019.02.003_bib0008","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheum."},{"issue":"1","key":"10.1016\/j.semarthrit.2019.02.003_bib0009","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/art.1780390105","volume":"39","author":"van Gestel","year":"1996","journal-title":"Arthritis Rheum."},{"issue":"12","key":"10.1016\/j.semarthrit.2019.02.003_bib0010","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1002\/art.39306","article-title":"Rheumatoid factor is associated with the distribution of hand joint destruction in rheumatoid arthritis","volume":"67","author":"Terao","year":"2015","journal-title":"Arthritis Rheumatol"},{"issue":"12","key":"10.1016\/j.semarthrit.2019.02.003_bib0011","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1136\/annrheumdis-2011-200353","article-title":"A large-scale association study identified multiple HLA-DRB1 alleles associated with ACPA-negative rheumatoid arthritis in Japanese subjects","volume":"70","author":"Terao","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.semarthrit.2019.02.003_bib0012","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1136\/annrheumdis-2011-200907","article-title":"Quantitative effect of HLA-DRB1 alleles to ACPA levels in Japanese rheumatoid arthritis: no strong genetic impact of shared epitope to ACPA levels after stratification of HLA-DRB1*09:01","volume":"71","author":"Terao","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.semarthrit.2019.02.003_bib0013","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0162896","article-title":"Immunogenicity and lupus-like autoantibody production can be linked to each other along with type I interferon production in patients with rheumatoid arthritis treated with infliximab: a retrospective study of a single center cohort","volume":"11","author":"Ishikawa","year":"2016","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.semarthrit.2019.02.003_bib0014","doi-asserted-by":"crossref","first-page":"6911","DOI":"10.1038\/s41598-017-07137-4","article-title":"Anti-centromere antibody exhibits specific distribution levels among anti-nuclear antibodies and may characterize a distinct subset in rheumatoid arthritis","volume":"7","author":"Kuramoto","year":"2017","journal-title":"Sci Rep"},{"issue":"9","key":"10.1016\/j.semarthrit.2019.02.003_bib0015","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1136\/annrheumdis-2014-205318","article-title":"What is the utility of routine ANA testing in predicting development of biological DMARD-induced lupus and vasculitis in patients with rheumatoid arthritis? Data from a single-centre cohort","volume":"73","author":"Takase","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.semarthrit.2019.02.003_bib0016","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1093\/rheumatology\/kep080","article-title":"Anti-TNF-induced lupus","volume":"48","author":"Williams","year":"2009","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.semarthrit.2019.02.003_bib0017","doi-asserted-by":"crossref","first-page":"R545","DOI":"10.1186\/ar1715","article-title":"Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey","volume":"7","author":"De Bandt","year":"2005","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"10.1016\/j.semarthrit.2019.02.003_bib0018","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s10067-009-1370-1","article-title":"Etanercept-induced anti-Jo-1-antibody-positive polymyositis in a patient with rheumatoid arthritis: a case report and review of the literature","volume":"29","author":"Ishikawa","year":"2010","journal-title":"Clin Rheumatol"},{"issue":"3","key":"10.1016\/j.semarthrit.2019.02.003_bib0019","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s10067-010-1666-1","article-title":"A case of antisynthetase syndrome in a rheumatoid arthritis patient with anti-PL-12 antibody following treatment with etanercept","volume":"30","author":"Ishikawa","year":"2011","journal-title":"Clin Rheumatol"},{"issue":"6","key":"10.1016\/j.semarthrit.2019.02.003_bib0020","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1007\/s11926-008-0072-z","article-title":"Vasculitis induced by tumor necrosis factor-targeted therapies","volume":"10","author":"Ramos-Casals","year":"2008","journal-title":"Curr Rheumatol Rep"},{"issue":"6","key":"10.1016\/j.semarthrit.2019.02.003_bib0021","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.jbspin.2006.02.010","article-title":"Vasculitides induced by TNFalpha antagonists: a study in 39 patients in France","volume":"73","author":"Saint Marcoux","year":"2006","journal-title":"Joint Bone Spine"},{"issue":"4","key":"10.1016\/j.semarthrit.2019.02.003_bib0022","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/MD.0b013e3181441a68","article-title":"Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases","volume":"86","author":"Ramos-Casals","year":"2007","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"10.1016\/j.semarthrit.2019.02.003_bib0023","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/nrrheum.2013.4","article-title":"Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis","volume":"9","author":"van Schouwenburg","year":"2013","journal-title":"Nat Rev Rheumatol"},{"issue":"4","key":"10.1016\/j.semarthrit.2019.02.003_bib0024","doi-asserted-by":"crossref","first-page":"R131","DOI":"10.1186\/ar2020","article-title":"Predictors of infusion reactions during infliximab treatment in patients with arthritis","volume":"8","author":"Kapetanovic","year":"2006","journal-title":"Arthritis Res Ther"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017218304360?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017218304360?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,11]],"date-time":"2019-09-11T05:12:46Z","timestamp":1568178766000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017218304360"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S0049017218304360"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2019.02.003","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-nuclear antibody development is associated with poor treatment response to biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2019.02.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}